Open AccessThis article is
- freely available
Rational Use of Antibiotics in the Treatment of Functional Bowel Disorders
Department of Medicine, University of Pavia, Foundation IRCCS S.Matteo Hospital, P.le C. Golgi 2, Pavia, Italy
* Author to whom correspondence should be addressed.
Received: 13 May 2010; in revised form: 8 July 2010 / Accepted: 13 July 2010 / Published: 26 July 2010
(This article belongs to the Special Issue Antibiotics
Abstract: Functional gastrointestinal symptoms such us bloating, fullness, flatulence, diarrhea, and constipation due to irritable bowel syndrome (IBS) were recently attributed to small bowel bacterial overgrowth, a condition depending on the presence of an increased number of bacteria in the small bowel. However, the methodology used to describe this association may be harshly criticized, since it has already been shown to be quite inaccurate. As a result an inappropriate use of antibiotics was consequently generated. In fact, antibiotics could be effective in the treatment of functional complaints, but only in a limited subgroup of patients, characterized by an increase of fermentation at colonic level. In this review, we have examined the papers suggesting a pathophysiological link between IBS and small bowel bacterial overgrowth, underlining its inappropriateness, and put forth our personal view on the rationale for antibiotic use in IBS.
Keywords: small intestine bacterial overgrowth; functional bowel disorders; irritable bowel syndrome; rifaximin; gas-related symptoms
Citations to this Article
Cite This Article
MDPI and ACS Style
Stefano, M.D.; Fasulo, R.; Corazza, G.R. Rational Use of Antibiotics in the Treatment of Functional Bowel Disorders. Pharmaceuticals 2010, 3, 2380-2386.
Stefano MD, Fasulo R, Corazza GR. Rational Use of Antibiotics in the Treatment of Functional Bowel Disorders. Pharmaceuticals. 2010; 3(8):2380-2386.
Stefano, Michele Di; Fasulo, Roberta; Corazza, Gino Roberto. 2010. "Rational Use of Antibiotics in the Treatment of Functional Bowel Disorders." Pharmaceuticals 3, no. 8: 2380-2386.